Van Hove JLK, Coughlin C II, Swanson M, Hennermann JB.
2002 Nov 14 [updated 2019 May 23]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026.
PMID:20301531
Nonketotic Hyperglycinemia: Insight into Current Therapies.
Nowak M, Chuchra P, Paprocka J.
J Clin Med. 2022 May 27;11(11):3027. doi: 10.3390/jcm11113027.
PMID:35683414
Biochemical and molecular predictors for prognosis in nonketotic hyperglycinemia.
Ann Neurol. 2015 Oct;78(4):606-18. doi: 10.1002/ana.24485. Epub 2015 Aug 10.
PMID:26179960
The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT.
Coughlin CR 2nd, Swanson MA, Kronquist K, Acquaviva C, Hutchin T, Rodríguez-Pombo P, Väisänen ML, Spector E, Creadon-Swindell G, Brás-Goldberg AM, Rahikkala E, Moilanen JS, Mahieu V, Matthijs G, Bravo-Alonso I, Pérez-Cerdá C, Ugarte M, Vianey-Saban C, Scharer GH, Van Hove JL.
Genet Med. 2017 Jan;19(1):104-111. doi: 10.1038/gim.2016.74. Epub 2016 Jun 30.
PMID:27362913
Nonketotic Hyperglycinemia.
Krawiec C, Anastasopoulou C.
2023 Mar 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
PMID:32310600
The role of NMDA-receptor type glutamatergic antagonists dextromethorphan or ketamine in the treatment of nonketotic hyperglycinemia: A critical reassessment.